EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma

Mir Lim; Joseph W. Franses; Robin Imperial; Umair Majeed; Jill Tsai; David Hsiehchen

doi:10.1053/j.gastro.2023.01.023

EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma

Mir Lim, Joseph W. Franses, Robin Imperial, Umair Majeed, Jill Tsai, David Hsiehchen

Research output: Contribution to journal › Short survey › peer-review

Original language	English (US)
Pages (from-to)	1006-1008.e3
Journal	Gastroenterology
Volume	164
Issue number	6
DOIs	https://doi.org/10.1053/j.gastro.2023.01.023
State	Published - May 2023

ASJC Scopus subject areas

Hepatology
Gastroenterology

Access to Document

10.1053/j.gastro.2023.01.023

Cite this

@article{2ece815021f948718f98d15350721bff,

title = "EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma",

author = "Mir Lim and Franses, {Joseph W.} and Robin Imperial and Umair Majeed and Jill Tsai and David Hsiehchen",

note = "Funding Information: Conflicts of interest These authors disclose the following: Joseph W. Franses receives consulting fees from Foundation Medicine and research support from Roche and Eisai. Jill Tsai is an employee of Guardant Health and holds ownership interest in Guardant Health. David Hsiehchen receives research support from Pfizer. The remaining authors disclose no conflicts. Funding Information: Funding David Hsiehchen is supported by Cancer Prevention and Research Institute of Texas (RP200549). ",

year = "2023",

month = may,

doi = "10.1053/j.gastro.2023.01.023",

language = "English (US)",

volume = "164",

pages = "1006--1008.e3",

journal = "Gastroenterology",

issn = "0016-5085",

publisher = "W.B. Saunders Ltd",

number = "6",

}

TY - JOUR

T1 - EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma

AU - Lim, Mir

AU - Franses, Joseph W.

AU - Imperial, Robin

AU - Majeed, Umair

AU - Tsai, Jill

AU - Hsiehchen, David

N1 - Funding Information: Conflicts of interest These authors disclose the following: Joseph W. Franses receives consulting fees from Foundation Medicine and research support from Roche and Eisai. Jill Tsai is an employee of Guardant Health and holds ownership interest in Guardant Health. David Hsiehchen receives research support from Pfizer. The remaining authors disclose no conflicts. Funding Information: Funding David Hsiehchen is supported by Cancer Prevention and Research Institute of Texas (RP200549).

PY - 2023/5

Y1 - 2023/5

UR - http://www.scopus.com/inward/record.url?scp=85151280492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85151280492&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2023.01.023

DO - 10.1053/j.gastro.2023.01.023

M3 - Short survey

C2 - 36708791

AN - SCOPUS:85151280492

SN - 0016-5085

VL - 164

SP - 1006-1008.e3

JO - Gastroenterology

JF - Gastroenterology

IS - 6

ER -

EGFR/ERBB2 Amplifications and Alterations Associated With Resistance to Lenvatinib in Hepatocellular Carcinoma

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this